ECSP13012724A - Anticuerpos para el receptor de la barrera hematoencefálica de baja afinidad y sus usos - Google Patents

Anticuerpos para el receptor de la barrera hematoencefálica de baja afinidad y sus usos

Info

Publication number
ECSP13012724A
ECSP13012724A ECSP13012724A ECSP13012724A EC SP13012724 A ECSP13012724 A EC SP13012724A EC SP13012724 A ECSP13012724 A EC SP13012724A EC SP13012724 A ECSP13012724 A EC SP13012724A
Authority
EC
Ecuador
Prior art keywords
antibodies
low affinity
barrier receptor
hematoencephalic barrier
hematoencephalic
Prior art date
Application number
Other languages
English (en)
Inventor
Mark Dennis
Ryan J Watts
Yin Zhang
Yunhua Joy Yu
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45316102&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP13012724(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of ECSP13012724A publication Critical patent/ECSP13012724A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)

Abstract

La presente invención se refiere a anticuerpos que se unen a los receptores de la barrera hematoencefálica (BBB-R) y los métodos de usar los mismos.
ECSP13012724 2010-11-30 2013-06-28 Anticuerpos para el receptor de la barrera hematoencefálica de baja afinidad y sus usos ECSP13012724A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41822310P 2010-11-30 2010-11-30

Publications (1)

Publication Number Publication Date
ECSP13012724A true ECSP13012724A (es) 2013-08-30

Family

ID=45316102

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13012724 ECSP13012724A (es) 2010-11-30 2013-06-28 Anticuerpos para el receptor de la barrera hematoencefálica de baja afinidad y sus usos

Country Status (34)

Country Link
US (5) US20120171120A1 (es)
EP (2) EP2646470B1 (es)
JP (3) JP6125430B2 (es)
KR (3) KR102099462B1 (es)
CN (2) CN110251668A (es)
AR (1) AR084020A1 (es)
AU (2) AU2011336716B2 (es)
BR (1) BR112013013083A2 (es)
CA (1) CA2818173C (es)
CL (1) CL2013001535A1 (es)
CO (1) CO6721052A2 (es)
CR (1) CR20130255A (es)
CY (1) CY1118906T1 (es)
DK (1) DK2646470T3 (es)
EA (1) EA034333B1 (es)
EC (1) ECSP13012724A (es)
ES (1) ES2631356T3 (es)
HR (1) HRP20170590T1 (es)
IL (1) IL282877A (es)
LT (1) LT2646470T (es)
MA (1) MA34749B1 (es)
MX (1) MX358367B (es)
MY (1) MY188469A (es)
NZ (2) NZ724348A (es)
PE (1) PE20140981A1 (es)
PL (1) PL2646470T3 (es)
PT (1) PT2646470T (es)
RS (1) RS55920B1 (es)
SG (1) SG190900A1 (es)
SI (1) SI2646470T1 (es)
TW (3) TWI689314B (es)
UA (1) UA117801C2 (es)
WO (1) WO2012075037A1 (es)
ZA (1) ZA201303572B (es)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8759297B2 (en) 2006-08-18 2014-06-24 Armagen Technologies, Inc. Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns
WO2009018122A2 (en) 2007-07-27 2009-02-05 Armagen Technologies, Inc. Methods and compositions for increasing alpha-iduronidase activity in the cns
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
ES2725200T3 (es) 2009-10-09 2019-09-20 Armagen Inc Métodos y composiciones para aumentar la actividad de iduronato 2-sulfatasa en el SNC
CN103298834A (zh) 2010-08-03 2013-09-11 Abbvie公司 双重可变结构域免疫球蛋白及其用途
CA2815840A1 (en) 2010-11-10 2012-05-18 Genentech, Inc. Methods and compositions for neural disease immunotherapy
TWI689314B (zh) 2010-11-30 2020-04-01 建南德克公司 低親和力血腦障壁受體抗體及其用途
BR112013019975A2 (pt) 2011-02-28 2017-08-01 Hoffmann La Roche proteínas de ligação de antígeno, composição farmacêutica, uso de uma proteína de ligação de antígeno, método para o tratamento de um paciente e método para a preparação de uma proteína de ligação de antígeno, ácido nucleico, vetor e célula hospedeira"
MX342034B (es) 2011-02-28 2016-09-12 Hoffmann La Roche Proteinas monovalentes que se unen a antigenos.
US20150353639A1 (en) * 2012-05-21 2015-12-10 Genentech, Inc. Methods for improving safety of blood-brain barrier transport
JP6148729B2 (ja) 2012-07-04 2017-06-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 共有結合している抗原−抗体結合体
LT2890712T (lt) * 2012-08-29 2019-07-25 F. Hoffmann-La Roche Ag Šaudyklinis nešiklis per kraujo ir smegenų barjerą
WO2014089209A2 (en) * 2012-12-04 2014-06-12 Abbvie, Inc. Blood-brain barrier (bbb) penetrating dual specific binding proteins
EP2970408B1 (en) 2013-03-12 2018-01-10 Amgen Inc. Potent and selective inhibitors of nav1.7
AR096927A1 (es) 2013-03-12 2016-02-10 Amgen Inc INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.7
US9546203B2 (en) 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
MA38632B1 (fr) * 2013-05-20 2019-10-31 Genentech Inc Anticorps anti-récepteur de transferrine et procédés d'utilisation
JP6692293B2 (ja) * 2013-07-22 2020-05-13 アーマジェン・インコーポレイテッドＡｒｍａｇｅｎ， Ｉｎｃ． Ｃｎｓにおける酵素活性を増大するための方法および組成物
US20160168253A1 (en) * 2013-08-02 2016-06-16 Hoffmann- La Roche Inc. Therapeutic fusion protein
NZ756750A (en) * 2013-09-13 2022-05-27 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
PL3044323T3 (pl) 2013-09-13 2022-06-27 F.Hoffmann-La Roche Ag Sposoby wykrywania i ilościowego oznaczania białka komórki gospodarza w liniach komórkowych
EP3055329B1 (en) 2013-10-11 2018-06-13 F. Hoffmann-La Roche AG Multispecific domain exchanged common variable light chain antibodies
SG10202007189VA (en) * 2013-11-21 2020-09-29 Hoffmann La Roche ANTI-alpha-SYNUCLEIN ANTIBODIES AND METHODS OF USE
US9579374B2 (en) 2013-12-04 2017-02-28 The Johns Hopkins University Method for rapidly designing pharmaceutical preparations for preventing viral infection
RS60031B1 (sr) 2013-12-20 2020-04-30 Hoffmann La Roche Humanizovana anti-tau(ps422) antitela i načini upotrebe
US10370692B2 (en) 2013-12-20 2019-08-06 Hoffmann-La Roche Inc. Recombinant polypeptide production methods
EP3088518A4 (en) 2013-12-25 2017-09-20 JCR Pharmaceuticals Co., Ltd. Novel anti-transferrin receptor antibody that passes through blood-brain barrier
EP3089759B1 (en) 2014-01-03 2018-12-05 F. Hoffmann-La Roche AG Covalently linked polypeptide toxin-antibody conjugates
WO2015101587A1 (en) 2014-01-03 2015-07-09 F. Hoffmann-La Roche Ag Covalently linked helicar-anti-helicar antibody conjugates and uses thereof
CN111228509A (zh) 2014-01-03 2020-06-05 豪夫迈·罗氏有限公司 双特异性抗-半抗原/抗-血脑屏障受体的抗体、其复合物及其作为血脑屏障穿梭物的应用
CN111057147B (zh) * 2014-01-06 2023-11-10 豪夫迈·罗氏有限公司 单价血脑屏障穿梭模块
CN106559993B (zh) 2014-03-06 2020-12-15 加拿大国家研究委员会 ***1受体特异性抗体及其用途
AU2014385801B2 (en) 2014-03-06 2020-11-12 National Research Council Of Canada Insulin-like growth factor 1 receptor -specific antibodies and uses thereof
DK3114142T3 (da) 2014-03-06 2019-09-16 Nat Res Council Canada Insulinlignende vækstfaktor 1-receptorspecifikke antistoffer og anvendelser deraf
US10562973B2 (en) 2014-04-08 2020-02-18 Prothena Bioscience Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
WO2015175375A1 (en) 2014-05-13 2015-11-19 Short Jay M Conditionally active biological proteins
US10941182B2 (en) 2014-06-10 2021-03-09 Amgen Inc. Apelin polypeptides
AR100978A1 (es) * 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
US11111288B2 (en) 2014-08-28 2021-09-07 Bioatla, Inc. Conditionally active chimeric antigen receptors for modified t-cells
EP3186284B1 (en) 2014-08-28 2022-04-06 BioAtla, Inc. Conditionally active chimeric antigen receptors for modified t-cells
EP3218411B1 (en) 2014-11-14 2022-01-12 Ossianix, Inc. Variable new antigen receptors (vnars) directed against transferrin receptor (tfr) and their use
CN107250158B (zh) * 2014-11-19 2022-03-25 基因泰克公司 抗转铁蛋白受体/抗bace1多特异性抗体和使用方法
EP3221364B1 (en) 2014-11-19 2020-12-16 Genentech, Inc. Antibodies against bace1 and use thereof for neural disease immunotherapy
EP3221362B1 (en) * 2014-11-19 2019-07-24 F.Hoffmann-La Roche Ag Anti-transferrin receptor antibodies and methods of use
PL3227332T3 (pl) 2014-12-03 2020-06-15 F. Hoffmann-La Roche Ag Wielospecyficzne przeciwciała
RU2017120039A (ru) * 2014-12-10 2019-01-10 Дженентек, Инк. Антитела к рецепторам гематоэнцефалического барьера и способы их применения
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
TN2017000432A1 (en) 2015-04-10 2019-04-12 Amgen Inc Interleukin-2 muteins for the expansion of t-regulatory cells
HUE057720T2 (hu) 2015-05-04 2022-06-28 Cytomx Therapeutics Inc Aktiválható anti-CD71 antitestek és ezek alkalmazási eljárásai
TWI614023B (zh) 2015-05-20 2018-02-11 免疫功坊股份有限公司 具有標的部分及效應部分的胜肽核多臂接合物
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
TWI787942B (zh) 2015-06-24 2022-12-21 日商Ｊｃｒ製藥股份有限公司 通過血腦障壁之抗人類運鐵蛋白受體抗體
US11130815B2 (en) 2015-06-24 2021-09-28 Jcr Pharmaceuticals Co., Ltd. Fusion proteins containing a BDNF and an anti-human transferrin receptor antibody
AR105089A1 (es) 2015-06-24 2017-09-06 Hoffmann La Roche ANTICUERPOS ANTI-TAU(pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN
PE20221008A1 (es) * 2015-06-24 2022-06-15 Hoffmann La Roche Anticuerpos anti-receptor de transferrina con afinidad disenada
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
PE20181004A1 (es) * 2015-10-02 2018-06-26 Hoffmann La Roche Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso
US20190161535A1 (en) * 2016-05-09 2019-05-30 Annexon, Inc. Compositions and methods for treating spinal muscular atrophy
ES2930255T3 (es) 2016-05-13 2022-12-09 Bioatla Inc Anticuerpos anti-Ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos
EP3484918A1 (en) 2016-07-14 2019-05-22 BioArctic Neuroscience AB Brain delivery protein
WO2018031424A1 (en) 2016-08-06 2018-02-15 Ossianix, Inc. In vivo methods for selecting peptides that cross the blood brain barrier, related compositions and methods of use
CN106442967B (zh) * 2016-09-27 2018-05-15 鸿运华宁（杭州）生物医药有限公司 一种检测跨膜蛋白单克隆抗体亲和力的方法
US10702589B2 (en) 2016-10-04 2020-07-07 Ann And Robert H. Lurie Children's Hospital Of Chicago Compositions and methods of treating neurological disorder and stress-induced conditions
AU2017385274B2 (en) 2016-12-26 2024-02-22 Jcr Pharmaceuticals Co., Ltd. Fusion protein including BDNF
EA201991577A1 (ru) 2016-12-26 2019-12-30 Джей Си Ар ФАРМАСЬЮТИКАЛЗ КО., ЛТД. Новые антитела против рецептора трансферрина человека, способные преодолевать гематоэнцефалический барьер
US10457717B2 (en) 2017-02-17 2019-10-29 Denali Therapeutics Inc. Engineered polypeptides
WO2018152326A1 (en) 2017-02-17 2018-08-23 Denali Therapeutics Inc. Engineered transferrin receptor binding polypeptides
US10143187B2 (en) 2017-02-17 2018-12-04 Denali Therapeutics Inc. Transferrin receptor transgenic models
US10363245B2 (en) 2017-02-22 2019-07-30 The Board Of Regents Of The University Of Texas System Methods for treating CNS lesions
EP3661961A4 (en) * 2017-08-02 2021-04-14 Stressmarq Biosciences Inc. ANTIBODIES BINDING TO ACTIVE ALPHA-SYNUCLEIN
ES2817910T3 (es) * 2017-08-04 2021-04-08 Alzheimur 2012 S L Uso de un anticuerpo antipresenilina para la prevención y/o tratamiento del cáncer
DK3665192T3 (da) * 2017-08-10 2023-10-09 Denali Therapeutics Inc Konstruerede transferrinreceptorbindende polypeptider
KR20200058510A (ko) 2017-10-02 2020-05-27 데날리 테라퓨틱스 인크. 효소 대체 요법 효소를 포함하는 융합 단백질
US11780932B2 (en) 2017-10-09 2023-10-10 Wisconsin Alumni Research Foundation Antibodies targeting glioblastoma stem-like cells and methods of use thereof
WO2019089395A1 (en) 2017-11-02 2019-05-09 Ossianix, Inc. Improved tfr-selective binding peptides capable of crossing the blood brain barrier
US10688191B2 (en) 2018-01-19 2020-06-23 Hr Biomed, Llc Delivery of a chemotherapy agent across the blood-brain barrier
CA3090519A1 (en) 2018-02-07 2019-08-15 Regeneron Pharmaceuticals, Inc. Methods and compositions for therapeutic protein delivery
EP3810186B1 (en) 2018-06-21 2022-09-28 Novo Nordisk A/S Novel compounds for treatment of obesity
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
CN112955153A (zh) 2018-08-02 2021-06-11 达因疗法公司 肌肉靶向复合物及其用于治疗肌养蛋白病的用途
US20210395381A1 (en) 2018-09-14 2021-12-23 Ossianix, Inc. Tfr-specific binding moieties and transcytosis method to select vnars that cross cellular barriers
KR20200047937A (ko) * 2018-10-26 2020-05-08 재단법인 목암생명과학연구소 Ids를 포함하는 융합 단백질 및 이의 용도
CA3125316A1 (en) * 2018-12-28 2020-07-02 Kyowa Kirin Co., Ltd. Bispecific antibody binding to tfr
AU2020206593A1 (en) 2019-01-09 2021-07-15 Centre National De La Recherche Scientifique Transferrin receptor-binding molecules, conjugates thereof and their uses
CN113711036A (zh) 2019-01-30 2021-11-26 真和制药有限公司 抗gal3抗体及其用途
CA3147369A1 (en) 2019-08-14 2021-02-18 Dalia BURZYN Extracellular vesicle-aso constructs targeting cebp/beta
WO2021030769A1 (en) 2019-08-14 2021-02-18 Codiak Biosciences, Inc. Extracellular vesicles with nras antisense oligonucleotides
CA3147680A1 (en) 2019-08-14 2021-02-18 Dalia BURZYN Extracellular vesicle-aso constructs targeting stat6
CA3147701A1 (en) 2019-08-14 2021-02-18 Codiak Biosciences, Inc. Extracellular vesicles with antisense oligonucleotides targeting kras
CA3147365A1 (en) 2019-08-14 2021-02-18 Joanne LIM Extracellular vesicle-nlrp3 antagonist
EP4028048A1 (en) 2019-09-09 2022-07-20 F. Hoffmann-La Roche AG Glucocerebrosidase mutants
US20230241089A1 (en) 2019-09-25 2023-08-03 Codiak Biosciences, Inc. Sting agonist comprising exosomes for treating neuroimmunological disorders
TWI739220B (zh) * 2019-11-26 2021-09-11 亞瑟瑞智科技管理顧問股份有限公司 包含克拉維酸與丙戊酸之組合物及其用途
PE20230036A1 (es) 2019-12-23 2023-01-10 Denali Therapeutics Inc Variantes de progranulina
CN115335062A (zh) * 2020-01-10 2022-11-11 达因疗法公司 肌肉靶向复合物及其用于调节与肌肉健康相关的基因的用途
IL294486A (en) * 2020-01-13 2022-09-01 Truebinding Inc Antibodies against gal3 and methods of use
US20230114434A1 (en) 2020-03-13 2023-04-13 Codiak Biosciences, Inc. Extracellular vesicles for treating neurological disorders
WO2021184021A1 (en) 2020-03-13 2021-09-16 Codiak Biosciences, Inc. Extracellular vesicle-aso constructs targeting pmp22
WO2021184020A1 (en) 2020-03-13 2021-09-16 Codiak Biosciences, Inc. Methods of treating neuroinflammation
EP4294421A2 (en) 2021-02-17 2023-12-27 Lonza Sales AG Extracellular vesicle-nlrp3 antagonist
CA3220572A1 (en) 2021-06-11 2022-12-15 Bioarctic Ab Bispecific binding molecule
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
PE20240895A1 (es) 2021-09-01 2024-04-24 Biogen Ma Inc Anticuerpos del receptor antitransferrina y usos de los mismos
WO2023166168A1 (en) 2022-03-03 2023-09-07 Vib Vzw Polystyrene sulfonate for use to treat neurodegenerative diseases
WO2023198661A1 (en) 2022-04-12 2023-10-19 F. Hoffmann-La Roche Ag Fusion proteins targeted to the central nervous system
US11931421B2 (en) 2022-04-15 2024-03-19 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating myotonic dystrophy
WO2024026494A1 (en) 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. Viral particles retargeted to transferrin receptor 1
WO2024026488A2 (en) 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a modified transferrin receptor locus
WO2024059056A1 (en) * 2022-09-12 2024-03-21 Emory University Methods of managing traumatic brain injury

Family Cites Families (201)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
JPS55113334A (en) 1979-02-23 1980-09-01 Hitachi Ltd Manufacture of passivation film
US4447547A (en) 1980-04-09 1984-05-08 University Patents, Inc. Immunoassay for measurement of reticulocytes, and immunoreactive reagents for use therein
US4332785A (en) 1980-04-09 1982-06-01 University Patents, Inc. Immunoassay for measurement of reticulocytes, and immunoreactive reagents for use therein
US4626507A (en) 1980-09-25 1986-12-02 The Salk Institute For Biological Studies Hybridomas producing monoclonal antibodies specific for a human cell surface glycoprotein
US4434156A (en) 1981-10-26 1984-02-28 The Salk Institute For Biological Studies Monoclonal antibodies specific for the human transferrin receptor glycoprotein
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4545985A (en) 1984-01-26 1985-10-08 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services Pseudomonas exotoxin conjugate immunotoxins
JPS6210017A (ja) 1985-07-04 1987-01-19 Mochida Pharmaceut Co Ltd トランスフエリンレセプタ−の精製方法
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4956453A (en) 1985-12-06 1990-09-11 Cetus Corporation Anti-human ovarian cancer immunotoxins and methods of use thereof
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4801575A (en) 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US4892827A (en) * 1986-09-24 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
IE64781B1 (en) 1987-03-11 1995-09-06 Erba Carlo Spa Immunoglobulin conjugates
US5728383A (en) 1987-10-05 1998-03-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Treatment of tumors of the central nervous system with immunotoxins
US5792458A (en) 1987-10-05 1998-08-11 The United States Of America As Represented By The Department Of Health And Human Services Mutant diphtheria toxin conjugates
US5352447A (en) 1987-10-05 1994-10-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunotoxins for treatment of intracranial lesions and as adjunct to chemotherapy
US5208021A (en) 1987-10-05 1993-05-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of preparing diphtheria immunotoxins
US5231000A (en) * 1987-10-08 1993-07-27 The Mclean Hospital Antibodies to A4 amyloid peptide
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
CA2006408A1 (en) 1988-12-27 1990-06-27 Susumu Iwasa Bispecific monoclonal antibody, its production and use
US5217713A (en) 1988-12-27 1993-06-08 Takeda Chemical Industries, Ltd. Cytotoxic bispecific monoclonal antibody, its production and use
CA2011099A1 (en) 1989-04-19 1990-10-19 Stephen C. Wardlaw Determination of lymphocyte reactivity to specific antigens in blood
US5292869A (en) 1989-04-27 1994-03-08 The Board Of Governors Of The University Method for isolating and purifying transferrin and lactoferrin receptor proteins from bacteria and the preparation of vaccines containing the same
US5141743A (en) 1989-04-27 1992-08-25 University Technologies International, Inc. Method for isolating and purifying transferrin and lactoferrin receptor proteins and vaccines containing the same
US5154924A (en) 1989-09-07 1992-10-13 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5527527A (en) 1989-09-07 1996-06-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5182107A (en) 1989-09-07 1993-01-26 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US6329508B1 (en) 1989-09-07 2001-12-11 Alkermes, Inc. Transferrin receptor reactive chimeric antibodies
US5672683A (en) 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
US5977307A (en) 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
WO1991014452A1 (en) 1990-03-27 1991-10-03 The Salk Institute For Biological Studies Method for inhibiting cell growth and compositions useful therefor
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
ES2329979T3 (es) 1990-08-23 2009-12-03 The University Of North Carolina At Chapel Hill Proteinas de union de transferencia de neisseria gonorrhoeae y neisseria meningitis. su uso como vacuna.
US5912336A (en) 1990-08-23 1999-06-15 University Of North Carolina At Chapel Hill Isolated nucleic acid molecules encoding transferrin binding proteins from Neisseria gonorrhoeae and Neisseria meningitidis
JPH04187096A (ja) 1990-11-20 1992-07-03 Takeda Chem Ind Ltd 二重特異性を有するハイブリッド・モノクローナル抗体
US6099842A (en) 1990-12-03 2000-08-08 The United States Of America As Represented By The Department Of Health And Human Services Recombinant immunotoxin composed of a single chain antibody reacting with the human transferrin receptor and diptheria toxin
DE4110409C2 (de) 1991-03-29 1999-05-27 Boehringer Ingelheim Int Neue Protein-Polykation-Konjugate
US6287792B1 (en) 1991-06-17 2001-09-11 The Regents Of The University Of California Drug delivery of antisense oligonucleotides and peptides to tissues in vivo and to cells using avidin-biotin technology
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
SK285046B6 (sk) 1991-07-25 2006-05-04 Idec Pharmaceuticals Corporation Chimérna protilátka, ktorá sa špecificky viaže na ľudský antigén, farmaceutický prostriedok s jej obsahom, spôsob jej výroby a použitie
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
JPH07509444A (ja) 1991-11-26 1995-10-19 アルカーメス・インコーポレーテツド トランスフェリンセレプター特異的抗体−神経薬又は診断薬複合体の製造法
JP3571337B2 (ja) 1992-02-11 2004-09-29 セル ジェネシス，インコーポレーテッド 遺伝子標的現象による同型遺伝子接合
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5648469A (en) 1992-04-20 1997-07-15 The Salk Institute For Biological Studies Monoclonal antibodies reactive with transferrin receptor cytoplasmic domain
FR2692592B1 (fr) 1992-06-19 1995-03-31 Pasteur Merieux Serums Vacc Fragments d'ADN codant pour les sous-unités du récepteur de la transferrine de Neisseria meningitidis et procédés les exprimant.
WO1994002178A1 (en) 1992-07-27 1994-02-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Targeting of liposomes to the blood-brain barrier
US6361779B1 (en) 1993-11-08 2002-03-26 Aventis Pasteur Limited Transferrin receptor genes
CN1990503A (zh) 1993-11-08 2007-07-04 康诺特实验室有限公司 嗜血杆菌属转铁蛋白受体基因
JPH09506262A (ja) 1993-12-08 1997-06-24 ジェンザイム・コーポレイション 特異的抗体の製造方法
IL112372A (en) 1994-02-07 2001-08-26 Res Dev Foundation Non-viral vector for the delivery of genetic information to cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6015555A (en) 1995-05-19 2000-01-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US5817789A (en) 1995-06-06 1998-10-06 Transkaryotic Therapies, Inc. Chimeric proteins for use in transport of a selected substance into cells
JP3973169B2 (ja) 1995-09-26 2007-09-12 栄研化学株式会社 トランスフェリン−トランスフェリンレセプター・コンプレックス測定試薬および測定方法
US6290970B1 (en) 1995-10-11 2001-09-18 Aventis Pasteur Limited Transferrin receptor protein of Moraxella
US6497881B1 (en) 1995-11-30 2002-12-24 New York University High efficiency tissue specific compound delivery system using streptavidin-protein a fusion protein
AU2112697A (en) 1996-02-09 1997-08-28 Pi-Wan Cheng Receptor ligand-facilitated delivery of biologically active molecules
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6090576A (en) 1996-03-08 2000-07-18 Connaught Laboratories Limited DNA encoding a transferrin receptor of Moraxella
US6440701B1 (en) 1996-03-08 2002-08-27 Aventis Pasteur Limited Transferrin receptor genes of Moraxella
WO1998022092A1 (en) 1996-11-22 1998-05-28 The Regents Of The University Of California Transport of liposomes across the blood-brain barrier
JPH10245400A (ja) 1997-02-28 1998-09-14 Eiken Chem Co Ltd トランスフェリンレセプターの安定化方法
PT994903E (pt) 1997-06-24 2005-10-31 Genentech Inc Metodos e composicoes para glicoproteinas galactosiladas
WO1999022764A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
AU2783099A (en) 1998-02-24 1999-09-06 Receptron, Inc. Receptor derived peptides as modulators of receptor activity
PT1068241E (pt) 1998-04-02 2007-11-19 Genentech Inc Variantes de anticorpos e respectivos fragmentos
DK2180007T4 (da) 1998-04-20 2017-11-27 Roche Glycart Ag Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet
US6891028B1 (en) 1998-11-06 2005-05-10 Cedars-Sinai Medical Center Nucleic acids encoding transferrin receptor-like proteins
CA2350415A1 (en) 1998-11-18 2000-05-25 Incyte Pharmaceuticals, Inc. Inflammation-associated genes
EP1131457B1 (en) 1998-11-19 2010-10-06 Georgetown University Systemic viral/ligand gene delivery system and gene therapy
MXPA01007170A (es) 1999-01-15 2002-07-30 Genentech Inc Variantes de polipeptidos con funcion efectora alterada.
US7780882B2 (en) 1999-02-22 2010-08-24 Georgetown University Simplified and improved method for preparing an antibody or an antibody fragment targeted immunoliposome for systemic administration of a therapeutic or diagnostic agent
AU3703100A (en) 1999-02-22 2000-09-14 Georgetown University Antibody fragment-targeted immunoliposomes for systemic gene delivery
GB9908195D0 (en) 1999-04-09 1999-06-02 Microbiological Res Authority Treatment of intracellular infection
US7241449B1 (en) 1999-04-12 2007-07-10 Aventis Pasteur Limited Transferrin receptor genes of moraxella
US6511967B1 (en) 1999-04-23 2003-01-28 The General Hospital Corporation Use of an internalizing transferrin receptor to image transgene expression
ATE405636T1 (de) 1999-06-16 2008-09-15 Boston Biomedical Res Inst Immunologische kontrolle des beta-amyloid gehaltes in vivo
US20040146516A1 (en) 1999-06-17 2004-07-29 Utah Ventures Ii L.P. Lumen-exposed molecules and methods for targeted delivery
AU6607100A (en) 1999-07-23 2001-02-13 Regents Of The University Of California, The Anti-growth factor receptor avidin fusion proteins as universal vectors for drugdelivery
CA2393292A1 (en) 1999-12-13 2001-06-21 Cambridge Antibody Technology Limited Brain specific binding members
WO2001074399A1 (fr) 2000-03-30 2001-10-11 Ajinomoto Co., Inc. Medicaments a long temps de conservation dans un tissu
SI2857516T1 (sl) 2000-04-11 2017-09-29 Genentech, Inc. Multivalentna protitelesa in njihove uporabe
US20020136732A1 (en) 2000-04-23 2002-09-26 Houston L. L. Compositions comprising carriers and transportable complexes
US6372250B1 (en) 2000-04-25 2002-04-16 The Regents Of The University Of California Non-invasive gene targeting to the brain
GB0027328D0 (en) 2000-06-23 2000-12-27 Aventis Pharma Inc Bioengineered vehicles for targeted nucleic acid delivery
US20020048550A1 (en) 2000-07-20 2002-04-25 Vallera Daniel A. Radiolabeled immunotoxins
ATE441663T1 (de) 2000-09-06 2009-09-15 Aventis Pharma Sa Verfahren und zusammensetzungen für amyloidosis- verbundene krankheiten
JP2002095476A (ja) 2000-09-20 2002-04-02 Eisai Co Ltd トランスフェリン受容体を介した遺伝子導入法
AU2002236499A8 (en) 2000-11-30 2009-12-03 Uab Research Foundation Receptor-mediated uptake of peptides that bind the human transferrin receptor
US20030165853A1 (en) 2000-12-04 2003-09-04 The Regents Of The University Of California Office Of Technology Transfer Antisense imaging of gene expression of the brain in vivo
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
DE10121982B4 (de) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
AU2002314794A1 (en) 2001-05-23 2002-12-03 New York University Detection of alzheimer's amyloid by magnetic resonance imaging
US20100081792A1 (en) 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
MXPA04001072A (es) 2001-08-03 2005-02-17 Glycart Biotechnology Ag Variantes de glicosilacion de anticuerpos que tienen citotoxicidad celulares dependiente de anticuerpos incrementada.
US20030226155A1 (en) 2001-08-30 2003-12-04 Biorexis Pharmaceutical Corporation Modified transferrin-antibody fusion proteins
WO2004019872A2 (en) 2002-08-30 2004-03-11 Biorexis Pharmaceutical Corporation Oral delivery of modified transferrin fusion proteins
AU2002323501C1 (en) 2001-08-30 2010-04-29 Biorexis Technology, Inc Modified transferrin fusion proteins
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
BR0213761A (pt) 2001-10-25 2005-04-12 Genentech Inc Composições, preparação farmacêutica, artigo industrializado, método de tratamento de mamìferos, célula hospedeira, método para a produção de uma glicoproteìna e uso da composição
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
JP2005518816A (ja) 2002-03-07 2005-06-30 カーネギー メロン ユニバーシティ 磁気共鳴イメージング用コントラスト剤及びそれに関する方法
US7998704B2 (en) 2002-03-07 2011-08-16 Carnegie Mellon University Methods for magnetic resonance imaging
WO2003084470A2 (en) 2002-04-02 2003-10-16 Arizeke Pharmaceuticals, Inc. Compositions and methods for targeted biological delivery of molecular carriers
DK1539221T3 (da) 2002-08-30 2010-05-03 Biorexis Pharmaceutical Corp Transferrin-fusionsproteinbiblioteker
CN1713920A (zh) 2002-08-30 2005-12-28 比奥雷克西斯药物公司 被修饰的转铁蛋白融合蛋白
AU2003286002B2 (en) 2002-11-08 2011-06-16 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
US20050142141A1 (en) 2002-11-27 2005-06-30 Pardridge William M. Delivery of enzymes to the brain
US20040102369A1 (en) 2002-11-27 2004-05-27 The Regents Of The University Of California Transport of basic fibroblast growth factor across the blood brain barrier
KR101111477B1 (ko) 2002-12-03 2012-02-23 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 치료제와 연결된 콜레스테롤을 포함하는 접합체
CA2512717A1 (en) 2003-01-09 2004-07-29 Arizeke Pharmaceuticals Inc. Compositions and methods for targeted biological delivery of molecular carriers
JP4187096B2 (ja) 2003-01-15 2008-11-26 独立行政法人科学技術振興機構 ３次元フォトニック結晶製造方法
KR101228204B1 (ko) * 2003-02-10 2013-01-31 투-비비비 홀딩 비.브이. 염증성 상태 하에 있는 뇌-혈관 장벽에서 차등 발현되는핵산
CN1788017B (zh) * 2003-02-10 2013-04-24 to-BBB控股股份有限公司 炎症状态下在血脑屏障中差异表达的核酸
WO2004078777A2 (en) 2003-03-04 2004-09-16 Biorexis Pharmaceutical Corporation Dipeptidyl-peptidase protected proteins
AU2003286870A1 (en) 2003-06-05 2005-01-04 Salk Institute For Biological Studies Targeting polypeptides to the central nervous system
US20070264236A1 (en) 2003-08-04 2007-11-15 Applied Research Systems Ars Holding N.V. Novel Therapeutic Fusion Proteins
US20050042298A1 (en) 2003-08-20 2005-02-24 Pardridge William M. Immunonanoparticles
JP2007512001A (ja) 2003-08-28 2007-05-17 バイオレクシス ファーマシューティカル コーポレイション Ｅｐｏミメティックペプチドおよび融合タンパク質
WO2005025511A2 (en) 2003-09-10 2005-03-24 Cedars-Sinai Medical Center Potassium channel mediated delivery of agents through the blood-brain barrier
CA2544865C (en) 2003-11-05 2019-07-09 Glycart Biotechnology Ag Cd20 antibodies with increased fc receptor binding affinity and effector function
US20050202075A1 (en) 2004-03-12 2005-09-15 Pardridge William M. Delivery of genes encoding short hairpin RNA using receptor-specific nanocontainers
ATE450549T1 (de) 2004-03-31 2009-12-15 Adnagen Ag Monoklonale antikörper mit spezifität für fetale erythroidzellen
WO2005094364A2 (en) 2004-03-31 2005-10-13 Chimeric Technologies, Inc. Iga antibody protein as a cytotoxic drug
PT1740616E (pt) 2004-04-30 2012-03-23 Inst Nat Sante Rech Med Anticorpo anti-rtf
US20060024232A1 (en) 2004-06-02 2006-02-02 Sidney Kimmel Cancer Center Imaging and therapeutic agents targeting proteins expressed on endothelial cell surface
CA2569692C (en) 2004-06-07 2015-07-21 Raven Biotechnologies, Inc. Transferrin receptor antibodies
WO2006004910A2 (en) 2004-06-28 2006-01-12 Transtarget Inc. Improved bispecific antibodies
CA2614068A1 (en) 2004-06-29 2006-08-24 Massachusetts Institute Of Technology Methods and compositions related to the modulation of intercellular junctions
CA2583202A1 (en) 2004-10-04 2006-04-27 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of macromolecules
EP1858546A4 (en) 2005-03-04 2009-03-04 Biorexis Pharmaceutical Corp MODIFIED TRANSFERRINFUSION PROTEINS
EP2279726A3 (en) 2005-05-26 2012-06-20 Biorest Ltd. Compositions and methods using same for delivering agents into a target organ protected by a blood barrier
JP2005321411A (ja) 2005-06-10 2005-11-17 Eiken Chem Co Ltd トランスフェリン−トランスフェリンレセプター・コンプレックス測定試薬および測定方法
US7736647B2 (en) 2005-06-15 2010-06-15 Monoclonal Antibodies Therapeutics Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells
EP1896588B1 (en) 2005-06-17 2009-08-12 National Research Council Of Canada NOVEL Aß-BINDING PROTEIN AND ITS PEPTIDE DERIVATIVES AND USES THEREOF
AU2006283726C1 (en) 2005-08-24 2015-05-07 Immunogen, Inc. Process for preparing maytansinoid antibody conjugates
EP1957093B1 (en) 2005-08-29 2017-04-12 SHASHOUA, Victor E. Neuroprotective and neurorestorative methods and compositions
US8124095B2 (en) 2005-10-07 2012-02-28 Armagen Technologies, Inc. Fusion proteins for delivery of erythropoietin to the CNS
US8142781B2 (en) 2005-10-07 2012-03-27 Armagen Technologies, Inc. Fusion proteins for blood-brain barrier delivery
JP2009511060A (ja) 2005-10-14 2009-03-19 バイオレクシス ファーマシューティカル コーポレーション ナトリウム利尿ペプチド修飾されたトランスフェリン融合タンパク質
CA2631981A1 (en) 2005-12-05 2007-06-14 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of binding partners
WO2007067596A2 (en) 2005-12-05 2007-06-14 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of antibodies
EP2808032B1 (en) 2005-12-12 2018-08-01 AC Immune S.A. A beta 1-42 specific monoclonal antibodies with therapeutic properties
WO2007103288A2 (en) 2006-03-02 2007-09-13 Seattle Genetics, Inc. Engineered antibody drug conjugates
US20070231300A1 (en) 2006-03-28 2007-10-04 Washington, University Of Covalent conjugates between endoperoxides and transferrin and lactoferrin receptor-binding agents
AU2007233831B2 (en) * 2006-03-30 2013-02-14 Glaxo Group Limited Antibodies against amyloid-beta peptide
WO2008054544A2 (en) 2006-05-22 2008-05-08 Immune Disease Institute, Inc. Method for delivery across the blood brain barrier
AU2007256639A1 (en) * 2006-06-07 2007-12-13 Wisconsin Alumni Research Foundation Blood-brain barrier targeting antibodies
CL2007002070A1 (es) 2006-07-14 2008-02-08 Ac Immune S A Genentech Inc Anticuerpo quimerico o humanizado, o fragmentos de ellos, que se adhieren especificamente a por lo menos un epitopo en la proteina beta-amiloide; molecula de acido nucleico que lo codifica; composicion que lo comprende; su uso para tratar enfermedade
CA2672147A1 (en) 2006-07-27 2008-01-31 University Of Virginia Patent Foundation System and method for intracranial implantation of therapeutic or diagnostic agents
US20090092660A1 (en) 2006-08-09 2009-04-09 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of particles
WO2008021412A2 (en) 2006-08-14 2008-02-21 Biorexis Pharmaceutical Corporation Interferon beta and transferrin fusion proteins
US8759297B2 (en) * 2006-08-18 2014-06-24 Armagen Technologies, Inc. Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns
WO2008027236A2 (en) 2006-08-30 2008-03-06 Genentech, Inc. Multispecific antibodies
WO2008033924A2 (en) 2006-09-12 2008-03-20 Board Of Regents Of The University Of Nebraska Methods and compositions for targeted delivery of therapeutic agents
WO2008033395A2 (en) 2006-09-14 2008-03-20 Biorexis Pharmaceutical Corporation Melanocortin and transferrin fusion proteins
WO2008050133A2 (en) 2006-10-27 2008-05-02 Zapaloid Limited Inhibition of beta-amyloid aggregation
CN101245107B (zh) * 2007-02-14 2010-10-13 中国人民解放军军事医学科学院生物工程研究所 抗人转铁蛋白受体人源抗体及其应用
EP2124916A1 (en) 2007-02-27 2009-12-02 Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Use of histone deacetylase inhibitors for the treatment of central nervous system metastases
PT2308514E (pt) 2007-03-23 2013-09-06 To Bbb Holding B V Conjugados para a administração orientada de medicamentos através da barreira hematoencefálica
EP1975178A1 (en) 2007-03-30 2008-10-01 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Transcytotic modular antibody
AU2008257419B2 (en) 2007-05-23 2013-10-24 The Trustees Of The University Of Pennsylvania Targeted carriers for intracellular drug delivery
NZ601843A (en) 2007-06-12 2014-01-31 Ac Immune Sa Monoclonal anti beta amyloid antibody
BRPI0812478A2 (pt) 2007-06-12 2017-05-16 Ac Immune Sa anticorpo quimérico ou um fragmento do mesmo, ou anticorpo humanizado ou um fragmento do mesmo, molécula de ácido nucleico, vetor de expressão, célula, composição, métodos de prevenir, tratar ou aliviar os efeitos d euma ou mais doenças, de diagnosticar uma doença ou condição associada com amilóide em um indivíduo, de determinar a extensão de carga de placa amiloidogênica em um tecido e/ou fluidos corporais de um indivíduo, de desagregar fibras beta-amilóides pré-formadas e de prevenir degradação de neurônios induzidas por abeta, kit de teste, região variável de cadeia, e, linhagem de célula
GB0711424D0 (en) 2007-06-13 2007-07-25 Novozymes Delta Ltd Recombinant transferrin mutants
US7973019B1 (en) 2007-10-03 2011-07-05 Alcon Research, Ltd. Transferrin/transferrin receptor-mediated siRNA delivery
GB0725065D0 (en) 2007-12-21 2008-01-30 Got A Gene Ab Method
PT2235064E (pt) 2008-01-07 2016-03-01 Amgen Inc Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática
US8420620B2 (en) 2008-01-24 2013-04-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Induced internalization of surface receptors
MX2010010776A (es) 2008-03-31 2010-10-26 Glaxo Group Ltd Fusiones y conjugados de farmaco.
US20110250199A1 (en) 2008-06-04 2011-10-13 The Government of the United States of America as represented by the Secretary of the Department.... Immunotoxins and uses thereof
WO2009155609A1 (en) * 2008-06-20 2009-12-23 Oklahoma Medical Research Foundation IMMUNOGENIC MEMAPSIN 2 β-SECRETASE PEPTIDES AND METHODS OF USE
US20100077498A1 (en) 2008-09-11 2010-03-25 Pardridge William M Compositions and methods for blood-brain barrier delivery in the mouse
WO2010037135A2 (en) 2008-09-29 2010-04-01 The Regents Of The University Of California Compounds for reversing and inhibiting protein aggregation, and methods for making and using them
US20100098693A1 (en) 2008-10-07 2010-04-22 Pardridge William M Compositions and methods for blood-brain barrier delivery of organophosphatases
CN106995495A (zh) 2009-01-12 2017-08-01 希托马克斯医疗有限责任公司 修饰抗体组合物及其制备和使用方法
US8530629B2 (en) * 2009-01-30 2013-09-10 Ab Biosciences, Inc. Lowered affinity antibodies and uses therefor
WO2010108048A2 (en) 2009-03-18 2010-09-23 Armagen Technologies, Inc. Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins
WO2010120262A1 (en) 2009-04-14 2010-10-21 Smith Holdings, Llc Methods and compositions for the treatment of medical conditions involving cellular programming
US8956614B2 (en) * 2009-06-15 2015-02-17 Vib Vzw BACE1 inhibitory antibodies
CA2768598A1 (en) 2009-07-22 2011-01-27 Cenix Bioscience Gmbh Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes
TW201109438A (en) * 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US9149544B2 (en) 2009-11-06 2015-10-06 The Penn State Research Foundation Bioconjugation of calcium phosphosilicate nanoparticles for selective targeting of cells in vivo
FR2953841B1 (fr) 2009-12-16 2011-12-30 Centre Nat Rech Scient Anticorps diriges contre le recepteur de la transferrine et leurs utilisations pour l'immunotherapie des tumeurs qui dependent du fer
EP3112382A1 (en) 2009-12-29 2017-01-04 Emergent Product Development Seattle, LLC Heterodimer binding proteins and uses thereof
US8734799B2 (en) 2010-04-13 2014-05-27 The Regents Of The University Of California Unconjugated anti-TfR antibodies and compositions thereof for the treatment of cancer
FR2959416B1 (fr) 2010-05-03 2012-06-22 Monoclonal Antibodies Therapeutics Mat Biopharma Utilisation d'anticorps anti-cd71 pour la preparation d'un medicament
TWI689314B (zh) 2010-11-30 2020-04-01 建南德克公司 低親和力血腦障壁受體抗體及其用途
JP6210017B2 (ja) 2014-04-17 2017-10-11 マツダ株式会社 自動変速機

Also Published As

Publication number Publication date
KR102052571B1 (ko) 2019-12-05
AU2016202447B2 (en) 2018-05-17
EA034333B1 (ru) 2020-01-29
EP2646470A1 (en) 2013-10-09
UA117801C2 (uk) 2018-10-10
KR20130137654A (ko) 2013-12-17
CN110251668A (zh) 2019-09-20
TWI689314B (zh) 2020-04-01
DK2646470T3 (en) 2017-05-08
US20150329636A1 (en) 2015-11-19
CO6721052A2 (es) 2013-07-31
MA34749B1 (fr) 2013-12-03
NZ724348A (en) 2019-12-20
KR102099462B1 (ko) 2020-04-10
PE20140981A1 (es) 2014-08-20
KR102188544B1 (ko) 2020-12-08
EA201390785A1 (ru) 2013-11-29
CL2013001535A1 (es) 2014-03-07
AU2011336716A1 (en) 2013-05-09
ES2631356T3 (es) 2017-08-30
CY1118906T1 (el) 2018-01-10
US20210292440A1 (en) 2021-09-23
TW201305200A (zh) 2013-02-01
RS55920B1 (sr) 2017-09-29
US20170260292A1 (en) 2017-09-14
JP6490721B2 (ja) 2019-03-27
CN103443125B (zh) 2019-05-03
JP2014500886A (ja) 2014-01-16
JP2019116485A (ja) 2019-07-18
HRP20170590T1 (hr) 2017-06-30
US9611323B2 (en) 2017-04-04
WO2012075037A1 (en) 2012-06-07
CN103443125A (zh) 2013-12-11
NZ706751A (en) 2016-10-28
US20120171120A1 (en) 2012-07-05
JP6800260B2 (ja) 2020-12-16
KR20190138314A (ko) 2019-12-12
AU2011336716B2 (en) 2016-01-21
BR112013013083A2 (pt) 2016-12-13
US20190202936A1 (en) 2019-07-04
MY188469A (en) 2021-12-10
ZA201303572B (en) 2017-06-28
SG190900A1 (en) 2013-07-31
US10941215B2 (en) 2021-03-09
EP2646470B1 (en) 2017-03-01
MX358367B (es) 2018-08-15
EP3208282A1 (en) 2017-08-23
CA2818173C (en) 2022-05-03
PL2646470T3 (pl) 2017-07-31
SI2646470T1 (sl) 2017-05-31
CR20130255A (es) 2013-09-18
MX2013005793A (es) 2013-07-22
JP2017105786A (ja) 2017-06-15
KR20200038560A (ko) 2020-04-13
AR084020A1 (es) 2013-04-17
TW201801743A (zh) 2018-01-16
TW202021621A (zh) 2020-06-16
JP6125430B2 (ja) 2017-05-10
PT2646470T (pt) 2017-05-03
IL282877A (en) 2021-06-30
CA2818173A1 (en) 2012-06-07
LT2646470T (lt) 2017-06-12

Similar Documents

Publication Publication Date Title
ECSP13012724A (es) Anticuerpos para el receptor de la barrera hematoencefálica de baja afinidad y sus usos
CY1121862T1 (el) Αντισωματα anti-phf-tau και χρησεις αυτων
GT201600085A (es) Composiciones y métodos para modular los receptores x farnesoides
DOP2016000145A (es) Reguladores de nrf2
CR20150502A (es) Anticuerpos biespecíficos específicos para fap y dr5, anticuerpos específicos para dr5 y métodos de utilización
CR20120215A (es) Anticuerpos contra csf-1r humano y usos de los mismos
ECSP13012794A (es) Anticuerpos anti-cd38
GT201300306A (es) Anticuerpos anti-angptl3 y usos de los mismos
CO7081144A2 (es) Anticuerpos biespecíficos contra tweak humana e il17 humana y usos de los mismos
CR20140146A (es) Anticuerpos anti-cd134 (ox40) y usos de los mismos
BR112015028870A2 (pt) estruturas fibrosas hidroentrelaçadas
GT201500024A (es) Heterociclos de 5 miembros que contienen nitrógeno sustituidos por carboxamida o sulfonamida como moduladores para el receptor nuclear huérfano rory
UA109931C2 (xx) Піримідинциклогексильні модулятори глюкокортикоїдних рецепторів
GT201400049A (es) "anticuerpos a pcsk9 y usos de los mismo"
ECSP11011517A (es) Compuestos antivirales
CR20120184A (es) Anticuerpos monoclonales frente a progastrina y su usos
ES2529890T8 (es) Agentes para el tratamiento de trastornos que implican la modulación de los receptores rianodina
ECSP13012519A (es) Compuestos sustituidos de benzamida
UY34165A (es) ?compuestos aldh-2 mitocondriales humanos para el tratamiento de la adicción?.
UY33957A (es) Moduladores de los receptores de hormonas nucleares
UY31622A1 (es) Antagonistas de aminoalquilbifenilo n,n-disubstituidos de receptores de prostaglandina d2
CR20160147A (es) Formulaciones de anticuerpos
UY35543A (es) N-(fenilcicloalquil)carboxamidas y n-(fenilcicloalquil)tiocarboxamidas nematicidas
EA201491357A1 (ru) Анти-lrp5 антитела и способы их применения
UY33909A (es) Metodo para producir fibra de lignina